The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy

Introduction: Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disease. It is characterized by persistent pruritus, usually occurring after 30 weeks of pregnancy, and by elevated levels of bile acids and transaminases, which decrease over the course of 2-3 week...

Full description

Bibliographic Details
Main Authors: Paulina Pawłowska, Alicja Ozga-Stachurska, Justyna Wójcik-Grudzień, Martyna Rozenbajgier
Format: Article
Language:English
Published: Kazimierz Wielki University 2022-09-01
Series:Journal of Education, Health and Sport
Subjects:
Online Access:https://apcz.umk.pl/JEHS/article/view/39712
_version_ 1811297544422031360
author Paulina Pawłowska
Alicja Ozga-Stachurska
Justyna Wójcik-Grudzień
Martyna Rozenbajgier
author_facet Paulina Pawłowska
Alicja Ozga-Stachurska
Justyna Wójcik-Grudzień
Martyna Rozenbajgier
author_sort Paulina Pawłowska
collection DOAJ
description Introduction: Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disease. It is characterized by persistent pruritus, usually occurring after 30 weeks of pregnancy, and by elevated levels of bile acids and transaminases, which decrease over the course of 2-3 weeks postpartum. [1,2]The occurrence of ICP in the mother may be associated with significant complications in the fetus, such as: preterm labor, intrauterine asphyxia, or sudden fetal death. Currently, the treatment of choice is ursodeoxycholic acid (UDCA).[2,6] Recently, it was observed that the administration of metformin in cases not responding to standard therapy improved lipid disorders in pregnant women.   The aim of the study:  The aim of the study is to present the possibility of using metformin in the treatment of ICP in pregnant women not responding to standard treatment and to present a clinical case.. Material and methods: The work is a review of the literature on the management of ICP and the use of metformin in the treatment of lipid metabolism disorders, as well as a brief case report of a patient with  intrahepatic cholestasis of pregnancy. Description of the state of knowledge: Metformin is an oral antidiabetic drug belonging to the group of biguanides. However, the latest observations show that metformin also has a beneficial effect on the liver function and on the lipid metabolism in pregnant women. In these patients, the levels of bile acids and liver enzymes decreased after the use of metformin. Summary: The mechanism of action of metformin explaining its beneficial effect on the lipid metabolism in pregnant women with intrahepatic cholestasis is not fully understood.
first_indexed 2024-04-13T06:06:00Z
format Article
id doaj.art-49ffd18b19ca4964b1a4884cef54ba91
institution Directory Open Access Journal
issn 2391-8306
language English
last_indexed 2024-04-13T06:06:00Z
publishDate 2022-09-01
publisher Kazimierz Wielki University
record_format Article
series Journal of Education, Health and Sport
spelling doaj.art-49ffd18b19ca4964b1a4884cef54ba912022-12-22T02:59:15ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062022-09-0112910.12775/JEHS.2022.12.09.048 The use of metformin in the treatment of Intrahepatic cholestasis of pregnancyPaulina Pawłowska0Alicja Ozga-Stachurska1Justyna Wójcik-Grudzień2Martyna Rozenbajgier3Wojewódzki Szpital Specjalistyczny im. Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w LublinieWojewódzki Szpital Specjalistyczny im. Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie Mazowiecki Szpital Specjalistyczny Sp. z o.o. w RadomiuWojskowy Szpital Kliniczny z Polikliniką w Krakowie Introduction: Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disease. It is characterized by persistent pruritus, usually occurring after 30 weeks of pregnancy, and by elevated levels of bile acids and transaminases, which decrease over the course of 2-3 weeks postpartum. [1,2]The occurrence of ICP in the mother may be associated with significant complications in the fetus, such as: preterm labor, intrauterine asphyxia, or sudden fetal death. Currently, the treatment of choice is ursodeoxycholic acid (UDCA).[2,6] Recently, it was observed that the administration of metformin in cases not responding to standard therapy improved lipid disorders in pregnant women.   The aim of the study:  The aim of the study is to present the possibility of using metformin in the treatment of ICP in pregnant women not responding to standard treatment and to present a clinical case.. Material and methods: The work is a review of the literature on the management of ICP and the use of metformin in the treatment of lipid metabolism disorders, as well as a brief case report of a patient with  intrahepatic cholestasis of pregnancy. Description of the state of knowledge: Metformin is an oral antidiabetic drug belonging to the group of biguanides. However, the latest observations show that metformin also has a beneficial effect on the liver function and on the lipid metabolism in pregnant women. In these patients, the levels of bile acids and liver enzymes decreased after the use of metformin. Summary: The mechanism of action of metformin explaining its beneficial effect on the lipid metabolism in pregnant women with intrahepatic cholestasis is not fully understood. https://apcz.umk.pl/JEHS/article/view/39712Intrahepatic cholestasis of pregnancymetforminlipid disordersICP
spellingShingle Paulina Pawłowska
Alicja Ozga-Stachurska
Justyna Wójcik-Grudzień
Martyna Rozenbajgier
The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy
Journal of Education, Health and Sport
Intrahepatic cholestasis of pregnancy
metformin
lipid disorders
ICP
title The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy
title_full The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy
title_fullStr The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy
title_full_unstemmed The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy
title_short The use of metformin in the treatment of Intrahepatic cholestasis of pregnancy
title_sort use of metformin in the treatment of intrahepatic cholestasis of pregnancy
topic Intrahepatic cholestasis of pregnancy
metformin
lipid disorders
ICP
url https://apcz.umk.pl/JEHS/article/view/39712
work_keys_str_mv AT paulinapawłowska theuseofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT alicjaozgastachurska theuseofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT justynawojcikgrudzien theuseofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT martynarozenbajgier theuseofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT paulinapawłowska useofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT alicjaozgastachurska useofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT justynawojcikgrudzien useofmetformininthetreatmentofintrahepaticcholestasisofpregnancy
AT martynarozenbajgier useofmetformininthetreatmentofintrahepaticcholestasisofpregnancy